Skip to content

Pulmonx Corporation LUNG Deferred Tax Assets and Other Non-Current Assets

Deferred Tax Assets and Other Non-Current Assets at other companies

Theravance Biopharma logo
Theravance BiopharmaTBPH
Savara logo
SavaraSVRA
LQD
Liquidia CorporationLQDA
United Therapeutics logo
United TherapeuticsUTHR
Zevra Therapeutics, Inc. logo
Zevra Therapeutics, Inc.ZVRA
LivaNova logo
LivaNovaLIVN

Other financials

Income statement

See full
Revenue$20.6M-8.7%
Gross profit$16.0M-1.8%
Operating income-$13.0M+11.0%
Net income-$13.7M+5.5%
EPS (diluted)-$0.33+8.3%

Balance sheet

See full
Cash & equivalents$61.0M-2.4%
Total debt$56.3M-1.2%
Total equity$45.8M-41.1%
Total assets$120.0M-20.4%

Cash flow

See full
Operating cash flow-$10.1M+23.6%
CapEx$9.0K-97.0%
Free cash flow-$10.1M+25.3%

Valuation

See full
Market cap$54.91M-43.7%
Enterprise value$50.17M-39.2%
P/S0.6×-0.5×

Profitability

See full
Gross margin75.5%+2.0pp
Operating margin-58.8%-5.8pp
Net margin-60.1%-4.4pp
FCF margin-33.2%-4.4pp

Returns & leverage

See full
Return on equity-86.2%+62.6pp
Debt / equity1.2×+0.5×
Current ratio4.9×-0.1×

Where this comes from

Reported directly by Pulmonx Corporation in its filing.

Tagged under the XBRL concept us-gaap:OtherAssetsNoncurrent.

The official record: Pulmonx Corporation’s 10-Q, filed May 4, 2026, on SEC EDGAR. View the filing →

Ask your AI about Pulmonx Corporation's deferred tax assets and other non-current assets.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Pulmonx Corporation's deferred tax assets and other non-current assets?
Pulmonx Corporation (LUNG) reported deferred tax assets and other non-current assets of $1.35M in Q1 2026.
How has Pulmonx Corporation's deferred tax assets and other non-current assets changed year-over-year?
Pulmonx Corporation's deferred tax assets and other non-current assets decreased by 14.3% year-over-year, from $1.58M to $1.35M.
What is the long-term trend for Pulmonx Corporation's deferred tax assets and other non-current assets?
Over 5 years (2020 to 2025), Pulmonx Corporation's deferred tax assets and other non-current assets has grown at a 21.5% compound annual growth rate (CAGR), from $536K to $1.42M.